Technical Analysis for RANI - Rani Therapeutics Holdings, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 200 DMA Support | Bullish | 0.53% | |
| Stochastic Buy Signal | Bullish | 0.53% | |
| Wide Bands | Range Expansion | 0.53% | |
| Oversold Stochastic | Weakness | 0.53% | |
| Doji - Bullish? | Reversal | -3.05% |
| Alert | Time |
|---|---|
| Up 2% | about 9 hours ago |
| Up 1% | about 9 hours ago |
| 10 DMA Resistance | 3 days ago |
| Down 5% | 3 days ago |
| Down 3% | 3 days ago |
Get a Trading Assistant
- Earnings date: 05/08/2024
Rani Therapeutics Holdings, Inc. Description
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was founded in 2012 and is headquartered in San Jose, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Diabetes Endocrine System Osteoporosis Peptide Hormones Growth Hormone Psoriatic Arthritis Glands Glucagon Growth Hormone Deficiency Neuroendocrine Tumors Acromegaly Hypoparathyroidism Neuroendocrinology Parathyroid Hormone
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.75 |
| 52 Week Low | 1.82 |
| Average Volume | 104,729 |
| 200-Day Moving Average | 3.59 |
| 50-Day Moving Average | 5.30 |
| 20-Day Moving Average | 4.14 |
| 10-Day Moving Average | 3.92 |
| Average True Range | 0.44 |
| RSI (14) | 38.27 |
| ADX | 17.39 |
| +DI | 14.13 |
| -DI | 22.61 |
| Chandelier Exit (Long, 3 ATRs) | 4.41 |
| Chandelier Exit (Short, 3 ATRs) | 4.85 |
| Upper Bollinger Bands | 4.82 |
| Lower Bollinger Band | 3.46 |
| Percent B (%b) | 0.27 |
| BandWidth | 32.95 |
| MACD Line | -0.35 |
| MACD Signal Line | -0.38 |
| MACD Histogram | 0.0255 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.10 | ||||
| Resistance 3 (R3) | 4.09 | 4.00 | 4.05 | ||
| Resistance 2 (R2) | 4.00 | 3.93 | 4.00 | 4.03 | |
| Resistance 1 (R1) | 3.91 | 3.88 | 3.91 | 3.91 | 4.02 |
| Pivot Point | 3.81 | 3.81 | 3.81 | 3.81 | 3.81 |
| Support 1 (S1) | 3.72 | 3.74 | 3.73 | 3.73 | 3.62 |
| Support 2 (S2) | 3.63 | 3.70 | 3.63 | 3.61 | |
| Support 3 (S3) | 3.54 | 3.63 | 3.59 | ||
| Support 4 (S4) | 3.54 |
